Bio-Medisinsk Innovasjon AS
This article was originally published in Start Up
Executive Summary
Failing hearts are able to bind more serotonin than normal hearts, which prompted the founders of Bio-Medisinsk Innovasjon to look for heart failure treatments in agents capable of inhibiting serotonin.
You may also be interested in...
Succeeding in Heart Failure, Incrementally
Because of the heterogeneity of heart failure patients and causes, new drugs to treat heart failure haven't been a huge area of research or business development. Few heart failure drugs are likely to be blockbusters, and there are very few deals around truly novel targets. Biotech start-ups build on known approaches and innovate incrementally, in this market.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.